Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole
Open accessAbstract
Maintaining therapeutic plasma concentrations of an antipsychotic agent is essential in preventing relapse of symptoms in schizophrenia. Long-acting injectable (LAI) formulations provide extended exposure to antipsychotic therapy and have been useful in addressing treatment nonadherence. Aripiprazole is an atypical antipsychotic used in the treatment of schizophrenia and is available in 2 chemically different (aripiprazole monohydrate and aripiprazole lauroxil [AL]) and pharmaceutically different LAI formulations (aripiprazole once-monthly 400 mg [AOM 400] and AL). The pharmaceutical difference is that AL, unlike AOM 400, is a prodrug that requires additional metabolic steps to form the active drug aripiprazole. We present data demonstrating that aripiprazole plasma concentrations are similar for AOM 400 and the 882 mg dose of AL when administered once every 4 weeks and that both provide similar therapeutic plasma concentrations of aripiprazole when compared with therapeutic oral doses.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Plasma concentrations from different formulations may reflect not just the dose administered but the absorption of the drug from the depot aripiprazole.
“Thus, plasma concentrations from different formulations may reflect not just the dose administered but the absorption of the drug from the depot aripiprazole [40].”
From Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview (2021) · cites this paper as [40]
The aripiprazole lauroxil 882 mg injection contains aripiprazole 600 mg whereas aripiprazole monohydrate 400 mg contains aripiprazole 400 mg.
“Although the aripiprazole lauroxil 882 mg injection contains aripiprazole 600 mg whereas aripiprazole monohydrate 400 mg contains aripiprazole 400 mg”
From Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview (2021) · cites this paper as [40]
Salzman et al. compared plasma concentrations of aripiprazole between once-monthly dosing of aripiprazole monohydrate 400 mg and aripiprazole lauroxil 882 mg.
“Salzman et al. [40] compared plasma concentrations of aripiprazole between once-monthly dosing of aripiprazole monohydrate 400 mg and aripiprazole lauroxil 882 mg.”
From Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview (2021) · cites this paper as [40]
Median steady-state plasma concentrations were similar between aripiprazole lauroxil 882 mg and aripiprazole monohydrate 400 mg.
“median steady-state plasma concentrations were similar”
From Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview (2021) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K. M., Fric, M., Gerlach, M., Greiner, C., Gründer, G., et al. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286287 · Cited by 862 · see citing works
Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development
Mould, D., & Upton, R. N. (2012) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.4 · Cited by 552 · see citing works
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Thibaut, F., Möller, H., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 418 · see citing works
Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia
Kane, J. M., Sanchez, R., Perry, P. P., Jin, N., Johnson, B. R., Forbes, R. A., McQuade, R. D., Carson, W. H., & Fleischhacker, W. W. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07530 · Cited by 361 · see citing works
Mallikaarjun, S., Salazar, D. E., & Bramer, S. L. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003261901 · Cited by 178 · see citing works
Fleischhacker, W. W., Sanchez, R., Perry, P. P., Jin, N., Peters-Strickland, T. S., Johnson, B. R., Baker, R. A., Eramo, A., McQuade, R. D., Carson, W. H., et al. (2014) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.113.134213 · Cited by 153 · see citing works
Self-citationMeltzer, H. Y., Risinger, R. C., Nasrallah, H. A., Du, Y., Zummo, J., Corey, L., Bose, A., Stankovic, S., Silverman, B. L., & Ehrich, E. W. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09741 · Cited by 116 · see citing works
Mallikaarjun, S., Kane, J. M., Bricmont, P., McQuade, R. D., Carson, W. H., Sanchez, R., Forbes, R. A., & Fleischhacker, W. W. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.06.041 · Cited by 108 · see citing works
Raoufinia, A., Peters-Strickland, T., Nylander, A.-G., Baker, R. A., Eramo, A., Jin, N., Bricmont, P., Repella, J., McQuade, R. D., Hertel, P., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw116 · Cited by 39 · see citing works
Self-citationBiological conversion of aripiprazole lauroxil − An N-acyloxymethyl aripiprazole prodrug
Rohde, M., M∅rk, N., Håkansson, A. E., et al. (2014) · Results in Pharma Sciences · doi:10.1016/j.rinphs.2014.04.002 · Cited by 25 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [4]Center for Drug Evaluation and Research Application Number: 202971Orig1s000 Clinical Pharmacology and Biopharmaceutics Review(s) Silver Spring Food and Drug Administration 2011
- [14]Center for Drug Evaluation and Research Application Number: 207533Orig1s000 Clinical Pharmacology and Biopharmaceutics Review(s) (Addendum to PBPK, Pharmacometric, Clin Pharm Reviews and Clin Pharm Addendum) and Pharmacometric Review Silver Spring Food and Drug Administration 2015
Cited by
Sorted by citations
Correll, C. U., Kim, E., Sliwa, J. K., Hamm, W., Gopal, S., Mathews, M., Venkatasubramanian, R., & Saklad, S. R. (2021) · CNS Drugs · doi:10.1007/s40263-020-00779-5 · Cited by 205 · see citing works
- Authors
- Salzman, P., Raoufinia, A., Legacy, S., Such, P., & Eramo, A.
- Affiliations
- Otsuka (United States) (US)
- Otsuka Pharmaceutical Development & Commercialization, Inc. (United States) (US)
- Lundbeck (Denmark) (DK)
- Lundbeck (United States) (US)
- Corresponding author
- Raoufinia, Arash
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2017-04
- Volume
- Volume 13
- Pages
- 1125-1129
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC5404798
- OpenAlex
- W2606184610
- Cited by
- 15
- References
- 10
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 1 · 2018: 1 · 2017: 1
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Otsuka Pharmaceutical
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- aripiprazole, long-acting injectables, aripiprazole lauroxil, plasma concentration, pharmacokinetics, prodrugs, atypical antipsychotics, schizophrenia, medication adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
